Norepinephrine Consumption After Prophylactic Ondansetron
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02928601|
Recruitment Status : Completed
First Posted : October 10, 2016
Last Update Posted : August 22, 2017
|Condition or disease||Intervention/treatment||Phase|
|Maternal Hypotension||Drug: Ondansetron Drug: Saline||Phase 4|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||108 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||Double (Participant, Care Provider)|
|Official Title:||Does Prophylactic Ondansetron Reduce Norepinephrine Consumption in Patients Undergoing Caesarean Section With Spinal Anesthesia?|
|Study Start Date :||November 2016|
|Actual Primary Completion Date :||August 2017|
|Actual Study Completion Date :||August 2017|
After spinal anesthesia, half of the patients will be given intravenous 8 mg ondansetron.
|Active Comparator: Saline||
After spinal anesthesia, half of the patients will be given intravenous 2 mlt saline.
- Norepinephrine consumption [ Time Frame: During the cesarean operation ]Whenever systolic arteriel pressure falls below 100 mmHg or below 20% of the preoperative baseline value in both groups norepinephrine (5 µg) will be administered intravenously and total consumption will be recorded.
- Bradicardia [ Time Frame: During the cesarean operation ]Heart rate lower than 60 beat /min will be treated with iv 0.5 mg of atropine and recorded.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02928601
|Adana, Turkey, 01330|
|Study Director:||Hakkı Ünlügenç, Professor||Çukurova University|